Apollon Formularies (AQSE:APOL) EBIT per Share : £-0.00 (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies EBIT per Share?

Apollon Formularies's EBIT per Share for the six months ended in Jun. 2023 was £-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was 64.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Apollon Formularies's EBIT per Share or its related term are showing as below:

AQSE:APOL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 64.8 Med: 64.8 Max: 64.8
Current: 64.8

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Apollon Formularies was 64.80% per year. The lowest was 64.80% per year. And the median was 64.80% per year.

AQSE:APOL's 3-Year EBIT Growth Rate is ranked better than
93.88% of 866 companies
in the Drug Manufacturers industry
Industry Median: 7.25 vs AQSE:APOL: 64.80

Apollon Formularies's EBIT for the six months ended in Jun. 2023 was £-0.40 Mil.

Apollon Formularies EBIT per Share Historical Data

The historical data trend for Apollon Formularies's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies EBIT per Share Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-0.02

-0.01

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
EBIT per Share	Get a 7-Day Free Trial											-	-0.01	-	-	-

Apollon Formularies EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Apollon Formularies's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.527	/	548.103
=	-0.00

Apollon Formularies's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.403	/	771.191
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.00

Apollon Formularies (AQSE:APOL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Apollon Formularies EBIT per Share Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.